questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Récepteurs de surface cellulaire
Récepteurs peptidiques
Récepteur facteur croissance
Récepteurs facteur croissance nerf
Récepteur facteur neurotrophique ciliaire
Récepteur facteur neurotrophique ciliaire : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Récepteur facteur neurotrophique ciliaire : Questions médicales les plus fréquentes",
"headline": "Récepteur facteur neurotrophique ciliaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Récepteur facteur neurotrophique ciliaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-06",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Récepteur facteur neurotrophique ciliaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Récepteurs facteur croissance nerf",
"url": "https://questionsmedicales.fr/mesh/D017475",
"about": {
"@type": "MedicalCondition",
"name": "Récepteurs facteur croissance nerf",
"code": {
"@type": "MedicalCode",
"code": "D017475",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Sous-unité alpha du récepteur du facteur neurotrophique ciliaire",
"alternateName": "Ciliary Neurotrophic Factor Receptor alpha Subunit",
"url": "https://questionsmedicales.fr/mesh/D053739",
"about": {
"@type": "MedicalCondition",
"name": "Sous-unité alpha du récepteur du facteur neurotrophique ciliaire",
"code": {
"@type": "MedicalCode",
"code": "D053739",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550.250.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Récepteur gp130 de cytokines",
"alternateName": "Cytokine Receptor gp130",
"url": "https://questionsmedicales.fr/mesh/D050822",
"about": {
"@type": "MedicalCondition",
"name": "Récepteur gp130 de cytokines",
"code": {
"@type": "MedicalCode",
"code": "D050822",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550.250.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Sous-unité alpha du récepteur au facteur d'inhibition de la leucémie",
"alternateName": "Leukemia Inhibitory Factor Receptor alpha Subunit",
"url": "https://questionsmedicales.fr/mesh/D053680",
"about": {
"@type": "MedicalCondition",
"name": "Sous-unité alpha du récepteur au facteur d'inhibition de la leucémie",
"code": {
"@type": "MedicalCode",
"code": "D053680",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550.250.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Récepteur facteur neurotrophique ciliaire",
"alternateName": "Receptor, Ciliary Neurotrophic Factor",
"code": {
"@type": "MedicalCode",
"code": "D020801",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Giovanni Tossetta",
"url": "https://questionsmedicales.fr/author/Giovanni%20Tossetta",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy."
}
},
{
"@type": "Person",
"name": "Antonio Giordano",
"url": "https://questionsmedicales.fr/author/Antonio%20Giordano",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy."
}
},
{
"@type": "Person",
"name": "Cuihong Jia",
"url": "https://questionsmedicales.fr/author/Cuihong%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA. Electronic address: jiac01@etsu.edu."
}
},
{
"@type": "Person",
"name": "Theo Hagg",
"url": "https://questionsmedicales.fr/author/Theo%20Hagg",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA."
}
},
{
"@type": "Person",
"name": "Jessica Perugini",
"url": "https://questionsmedicales.fr/author/Jessica%20Perugini",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Case of Chronic Heart Failure Complicated by Primary Biliary Cholangitis and Skeletal Myopathy.",
"datePublished": "2022-09-14",
"url": "https://questionsmedicales.fr/article/36104226",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1536/ihj.21-837"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of antimicrobial therapy termination in febrile and afebrile patients with acute cholangitis after drainage.",
"datePublished": "2024-08-01",
"url": "https://questionsmedicales.fr/article/39090409",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-68999-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Use of Inflammatory Markers for Treatment Response Monitoring in Acute Cholangitis: A Retrospective Cohort Study.",
"datePublished": "2023-09-10",
"url": "https://questionsmedicales.fr/article/37690382",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jss.2023.07.047"
}
},
{
"@type": "ScholarlyArticle",
"name": "Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.",
"datePublished": "2022-12-31",
"url": "https://questionsmedicales.fr/article/36593158",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.dld.2022.12.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cystohepatic duct can be the bridge of calculous cholecystitis complicating cholangitis and obstructive jaundice.",
"datePublished": "2022-12-18",
"url": "https://questionsmedicales.fr/article/36529506",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5582/ddt.2022.01078"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Récepteurs de surface cellulaire",
"item": "https://questionsmedicales.fr/mesh/D011956"
},
{
"@type": "ListItem",
"position": 6,
"name": "Récepteurs peptidiques",
"item": "https://questionsmedicales.fr/mesh/D018000"
},
{
"@type": "ListItem",
"position": 7,
"name": "Récepteur facteur croissance",
"item": "https://questionsmedicales.fr/mesh/D017978"
},
{
"@type": "ListItem",
"position": 8,
"name": "Récepteurs facteur croissance nerf",
"item": "https://questionsmedicales.fr/mesh/D017475"
},
{
"@type": "ListItem",
"position": 9,
"name": "Récepteur facteur neurotrophique ciliaire",
"item": "https://questionsmedicales.fr/mesh/D020801"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Récepteur facteur neurotrophique ciliaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Récepteur facteur neurotrophique ciliaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Récepteur facteur neurotrophique ciliaire",
"description": "Comment diagnostiquer une dysfonction du récepteur CNTF ?\nQuels examens sont utilisés pour évaluer le récepteur CNTF ?\nY a-t-il des biomarqueurs pour le récepteur CNTF ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels symptômes peuvent indiquer un problème avec le CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Récepteur facteur neurotrophique ciliaire",
"description": "Quels sont les symptômes d'une déficience en CNTF ?\nLa douleur neuropathique est-elle liée au CNTF ?\nPeut-on observer des troubles moteurs avec le CNTF ?\nLes troubles sensoriels sont-ils associés au CNTF ?\nY a-t-il des signes cliniques spécifiques au CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Récepteur facteur neurotrophique ciliaire",
"description": "Peut-on prévenir les troubles liés au CNTF ?\nY a-t-il des mesures préventives spécifiques ?\nL'exercice régulier aide-t-il à prévenir les troubles du CNTF ?\nUne alimentation équilibrée peut-elle aider ?\nLe stress a-t-il un impact sur le CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Récepteur facteur neurotrophique ciliaire",
"description": "Quels traitements sont disponibles pour les troubles du CNTF ?\nLes thérapies géniques peuvent-elles aider le CNTF ?\nLes médicaments anti-inflammatoires sont-ils efficaces ?\nLa physiothérapie est-elle recommandée ?\nY a-t-il des traitements expérimentaux pour le CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Récepteur facteur neurotrophique ciliaire",
"description": "Quelles complications peuvent survenir avec le CNTF ?\nLe CNTF peut-il entraîner des troubles cognitifs ?\nY a-t-il un risque de dépendance aux médicaments ?\nLes complications sont-elles réversibles ?\nLe CNTF peut-il affecter la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Récepteur facteur neurotrophique ciliaire",
"description": "Quels sont les facteurs de risque pour les troubles du CNTF ?\nL'âge est-il un facteur de risque pour le CNTF ?\nLe sexe influence-t-il le risque de troubles du CNTF ?\nLes infections peuvent-elles augmenter le risque ?\nLe mode de vie influence-t-il le risque de troubles ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction du récepteur CNTF ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests neurologiques et des analyses génétiques."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer le récepteur CNTF ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des IRM et des électromyogrammes peuvent être utilisés pour évaluer la fonction nerveuse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs pour le récepteur CNTF ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de biomarqueurs spécifiques pour le récepteur CNTF."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie n'est généralement pas nécessaire pour diagnostiquer les troubles liés au CNTF."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec le CNTF ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la faiblesse musculaire ou des douleurs neuropathiques peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en CNTF ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent faiblesse musculaire, douleurs chroniques et troubles sensoriels."
}
},
{
"@type": "Question",
"name": "La douleur neuropathique est-elle liée au CNTF ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le CNTF joue un rôle dans la modulation de la douleur neuropathique."
}
},
{
"@type": "Question",
"name": "Peut-on observer des troubles moteurs avec le CNTF ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles moteurs peuvent survenir en raison d'une dysfonction du CNTF."
}
},
{
"@type": "Question",
"name": "Les troubles sensoriels sont-ils associés au CNTF ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles sensoriels peuvent être observés en cas de dysfonction du CNTF."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques au CNTF ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hypersensibilité ou l'engourdissement peuvent être spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés au CNTF ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les traumatismes nerveux et gérer les maladies chroniques peut aider."
}
},
{
"@type": "Question",
"name": "L'exercice régulier aide-t-il à prévenir les troubles du CNTF ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut renforcer les muscles et améliorer la santé nerveuse."
}
},
{
"@type": "Question",
"name": "Une alimentation équilibrée peut-elle aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments favorise la santé nerveuse et musculaire."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le CNTF ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la fonction nerveuse et aggraver les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles du CNTF ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies médicamenteuses et des interventions physiques."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles aider le CNTF ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur l'utilisation de thérapies géniques pour cibler le CNTF."
}
},
{
"@type": "Question",
"name": "Les médicaments anti-inflammatoires sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire l'inflammation et améliorer les symptômes liés au CNTF."
}
},
{
"@type": "Question",
"name": "La physiothérapie est-elle recommandée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la physiothérapie peut aider à améliorer la fonction musculaire et réduire la douleur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour le CNTF ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux, comme les thérapies biologiques, sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le CNTF ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent la progression des troubles neurologiques et la douleur chronique."
}
},
{
"@type": "Question",
"name": "Le CNTF peut-il entraîner des troubles cognitifs ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs peuvent survenir en raison de la dysfonction du CNTF."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de dépendance aux médicaments ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent entraîner une dépendance, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Le CNTF peut-il affecter la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles liés au CNTF peuvent significativement affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles du CNTF ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et des traumatismes."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour le CNTF ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de troubles liés au CNTF augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de troubles du CNTF ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines études montrent que le sexe peut influencer le risque de troubles."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles augmenter le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher des troubles liés au CNTF."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de troubles ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
}
]
}
]
}
Several autoantigens related to inflammatory myopathy have been identified. Antimitochondrial antibody M2 (AMA-M2) is known as one of the serologic hallmarks of primary biliary cholangitis (PBC). Ther...
The standard treatment duration for acute cholangitis (AC) involves a 4-7-day antimicrobial treatment post-biliary drainage; however, recent studies have suggested that a ≤ 2-3 days is sufficient. How...
In acute cholangitis (AC), monitoring treatment response to antimicrobial therapy allows for making timely decisions on early biliary decompression. The aims of this study were to compare the discrimi...
This was a retrospective cohort study. Patients who underwent endoscopic retrograde cholangio-pancreaticography for AC and those without biliary tract inflammation were randomly selected in the 4:3 ra...
The discriminating powers of the neutrophil count, lymphocytes, albumin, neutrophil-to-lymphocyte ratio, and CRP were superior to that of white blood cell (P1 < 0.005; P2 = 0.004; P3 < 0.0005; P4 < 0....
CLR and CLAR have superior discriminating powers than traditional inflammatory markers used for monitoring treatment response in AC....
Several ursodeoxycholic acid (UDCA) treatment response definitions have been introduced in primary biliary cholangitis (PBC). However, the lack of a gold standard results in heterogeneity in second-li...
This study aimed to explore which UDCA treatment response endpoint serves as the most accurate predictive model of long-term outcome....
A systematic review and meta-analysis of UDCA treatment response endpoints (and corresponding validations) were performed....
Sixteen individual UDCA treatment response endpoints and 96 external validations were found. Barcelona, Paris-1, Paris-2, Rotterdam, Toronto and GLOBE and UK-PBC Risk Scores are currently most robustl...
The GLOBE and UK-PBC Risk Scores are the most suitable for the real-world allocation of second-line therapies (obeticholic acid and fibrates). However, in the wake of the recent findings, alkaline pho...
Cholestasis and obstructive jaundice can be extrahepatic or intrahepatic. Here we present one case with calculous cholecystitis who presenting with repeated obstructive jaundice and without bile duct ...
There are no longitudinal studies on the epidemiology of primary biliary cholangitis (PBC) in Korea. This study aimed to elucidate the temporal trends in the epidemiology and outcomes of PBC in South ...
The epidemiology and outcomes of PBC were estimated using data from the Korean National Health Service database. Temporal trends in the PBC incidence and prevalence were analyzed using join-point regr...
The age and sex-standardized incidence between 2010 and 2019 (total patients, 4230) was 1.03 per 100,000 per year on average and increased from 0.71 to 1.14 per 100,000 with an annual percent change (...
The incidence and prevalence of PBC in Korea increased significantly between 2009 and 2019. Male sex and low adherence to UDCA were poor prognostic factors for PBC....
Objective A positive hemoculture in acute cholangitis is serious, but a blood culture result cannot be obtained at the initial diagnosis and so cannot be used for the severity assessment and decision-...
Inflammatory bowel disease (IBD) coexists in up to 80% of patients with primary sclerosing cholangitis (PSC). The aim of this study is to investigate the outcomes of immunomodulator (IMM)/advanced the...
This was a single-center, retrospective study of patients with PSC from 1 January 2012 to 1 April 2021. Adult patients (age ≥ 18 years) with PSC-IBD were included. Primary outcomes were rates and pred...
A total of 106 patients with PSC were reviewed and 72 (68%) with confirmed PSC-IBD were included in the study. The median age was 48 years (IQR, 33-59.5) and 69.4% were male. Overall, 28 patients (38....
In our cohort, up to a third of patients with PSC-IBD required IMM/advanced therapies with only 50% of these patients achieving endoscopic healing. The use of IMM/advanced therapies was not associated...
Factors that determine individual disease course of patients with primary sclerosing cholangitis (PSC) are poorly understood. Although an association between gut microbes and disease outcome has been ...
We analyzed microbial cultures from bile specimens obtained during routine endoscopic retrograde cholangiopancreatography (ERCP) and intraoperatively before liver transplantation in 114 patients with ...
A total of 87 patients (76%) had positive bile culture results. The presence of concomitant inflammatory bowel disease (IBD) was associated with positive bile culture results in multivariate analysis ...
Our data indicate that in patients with PSC, presence of Enterococcus spp. and Candida spp. in bile is associated with an adverse outcome. Concomitant IBD is linked to presence of microbes in bile, an...
Cholangitis after liver transplantation may lead to bile duct necrosis. Early diagnosis is essential to prevent graft loss. We aimed to investigate cholangitis related hepatic arterial Doppler ultraso...
Patients complicated with biopsy proven cholangitis in grafts were prospectively evaluated. Vascular complications were excluded. Doppler ultrasonography parameters including hepatic arterial diameter...
The mean hepatic arterial volume flow, resistive index, and diameter of 33 patients complicated with cholangitis was observed to decrease after recovery from 0.356 to 0.273 L/min (p = 0.007), from 0.6...
Ultrasound follow-ups after liver transplantation can give us the clue of cholangitis initiation through some altering hepatic arterial Doppler parameters. Even though these are nonspecific findings t...